Literature DB >> 30032321

Prostate cancer imaging: when the game gets tough, the hard one gets done!

Laura Evangelista1, Matteo Sepulcri2, Marco Maruzzo3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30032321     DOI： 10.1007/s00259-018-4092-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  14 in total

1.  Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.

Authors:  Marino Cimitan; Laura Evangelista; Marina Hodolič; Giuliano Mariani; Tanja Baseric; Valentina Bodanza; Giorgio Saladini; Duccio Volterrani; Anna Rita Cervino; Michele Gregianin; Giulia Puccini; Federica Guidoccio; Jure Fettich; Eugenio Borsatti
Journal:  J Nucl Med       Date:  2014-12-31       Impact factor: 10.057

2.  Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?

Authors:  Sotirios Chondrogiannis; Maria Cristina Marzola; Alice Ferretti; Gaia Grassetto; Anna Margherita Maffione; Lucia Rampin; Stefano Fanti; Francesco Giammarile; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-25       Impact factor: 9.236

Review 3.  Is There Use for FDG-PET in Prostate Cancer?

Authors:  Hossein Jadvar
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

4.  68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.

Authors:  Paola Caroli; Israel Sandler; Federica Matteucci; Ugo De Giorgi; Licia Uccelli; Monica Celli; Flavia Foca; Domenico Barone; Antonino Romeo; Anna Sarnelli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-19       Impact factor: 9.236

Review 5.  New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

Authors:  Laura Evangelista; Alberto Briganti; Stefano Fanti; Stephen Joniau; Sven Reske; Riccardo Schiavina; Christian Stief; George N Thalmann; Maria Picchio
Journal:  Eur Urol       Date:  2016-02-02       Impact factor: 20.096

6.  Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.

Authors:  Ingo Einspieler; Isabel Rauscher; Charlotte Düwel; Markus Krönke; Christoph Rischpler; Gregor Habl; Sabrina Dewes; Armin Ott; Hans-Jürgen Wester; Markus Schwaiger; Tobias Maurer; Matthias Eiber
Journal:  J Nucl Med       Date:  2017-02-16       Impact factor: 10.057

7.  68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

Authors:  Thomas A Hope; Charles Truillet; Eric C Ehman; Ali Afshar-Oromieh; Rahul Aggarwal; Charles J Ryan; Peter R Carroll; Eric J Small; Michael J Evans
Journal:  J Nucl Med       Date:  2016-09-22       Impact factor: 10.057

8.  Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.

Authors:  Giampiero Giovacchini; Maria Picchio; Elisa Coradeschi; Valentino Bettinardi; Luigi Gianolli; Vincenzo Scattoni; Cesare Cozzarini; Nadia Di Muzio; Patrizio Rigatti; Ferruccio Fazio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-15       Impact factor: 9.236

9.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Authors:  Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-12       Impact factor: 9.236

10.  Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.

Authors:  B Meller; F Bremmer; C O Sahlmann; S Hijazi; C Bouter; L Trojan; J Meller; P Thelen
Journal:  EJNMMI Res       Date:  2015-11-17       Impact factor: 3.138
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.